Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart ultrasound may predict who needs extra care

NCT ID NCT07439159

Knowledge-focused Sponsor: Istanbul University - Cerrahpasa Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether early heart ultrasound results can predict which patients hospitalized with heart failure will need to return to the hospital or have a higher risk of death. Researchers will measure heart structure and function before starting IV diuretics in 76 adults. The goal is to improve how doctors assess risk and make treatment decisions for these patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better predict which heart failure patients are at highest risk, leading to more personalized treatment plans.
What could go wrong
This is a small, observational study that does not test a new treatment. The findings may not apply to all heart failure patients and need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 76 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of adult patients hospitalized for acute decompensated heart failure at Istanbul University-Cerrahpaşa Cardiology Institute Hospital. Participants will be selected from patients presenting to the emergency department or cardiology outpatient clinics who require inpatient management for heart failure decompensation.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years. * Hospitalization due to acute decompensated heart failure. * Intravenous diuretic therapy deemed necessary by the treating cardiologist. * Predominant left-sided heart failure. * Provision of written informed consent prior to participation. Exclusion Criteria: * Severe anemia (hemoglobin \<7 g/dL). * Requirement for renal replacement therapy, including hemodialysis or peritoneal dialysis, or being listed for kidney transplantation. * Severe primary mitral regurgitation. * Severe aortic stenosis. * Severe aortic regurgitation. * Severe primary tricuspid regurgitation. * Primary right heart failure. * Heart failure secondary to congenital heart disease. * History of mitral valve replacement. * History of aortic valve replacement. * History of bioprosthetic valve replacement. * History of transcatheter aortic valve implantation. * Presence of active malignancy. * Failure to provide written informed consent. * Inability to perform transthoracic echocardiography prior to intravenous diuretic therapy for any reason.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute decompensated heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istanbul University Cerrahpaşa Institute of Cardiology

    RECRUITING

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.